Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism
Trial Timeline
Feb 1, 2004 → Dec 1, 2005
NCT ID
NCT01084265About Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG)
Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG) is a phase 3 stage product being developed by Merck for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT01084265. Target conditions include Hypogonadism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01084265 | Phase 3 | Completed |
Competing Products
20 competing products in Hypogonadism